$HEIA (-1,33 %)
$EL (+0,5 %)
$NUE (-0,34 %)
$CDNS (+0,32 %)
$WM (+0,99 %)
$MSFT (-0,12 %)
$V (+0,83 %)
$OR (+0,23 %)
$AZN (+2,18 %)
$MRK (-0,33 %)
$PG (-0,18 %)
$SBUX (-0,98 %)
$BCS (+1,42 %)
$META (-2,32 %)
$BABA (-0,87 %)
$QCOM (-0,19 %)
$AIR (+0,85 %)
$HSBC (+1,24 %)
$GSK (-1,92 %)
$MBG (+2,07 %)
$F (+2,97 %)
$AAPL (-0,09 %)
$AMZN (-1,29 %)
$MA (+0,71 %)
$7203 (+0,8 %)
$SHEL (+1,6 %)
$005930
$SNY (+1,41 %)
$CMCSA (+1,4 %)
$COIN (+1,92 %)
$NET (-4,06 %)
$XOM (+1,21 %)
$CVX (-0,14 %)
$CS (-1,04 %)
$NTDOY (-0,27 %)
$CL (-0,37 %)
$DTG (+0,79 %)
$UNH (+1,62 %)
Discussion sur SNY
Postes
2Quarterly figures 28.07-01.08



Sanofi reported earnings Q4 FY2024 results ended on December 31, 2024
- Revenue: €10.56B, +10.3% YoY at CER
- Net income: €683M vs -€555M in Q4 2023
- Business EPS: €1.31, -11.0% YoY at CER
- Full year revenue: €41.1B, +11.3% YoY at CER
CEO Paul Hudson: "We achieved double-digit sales growth in 2024 while pursuing the transformation of the company. Innovation was a key driver of our growth as launches already contributed 11 percent of sales, with Beyfortus becoming a blockbuster in its first full year of sales."
🌱Revenue & Growth
- US sales: €5.15B, +13.3% YoY at CER
- Europe sales: €2.43B, +6.0% YoY at CER
- Rest of World: €2.98B, +8.8% YoY at CER
- Dupixent sales: €3.46B, +16.0% YoY at CER
- Vaccines sales: €2.18B, +10.8% YoY at CER
💰Profits & Financials
- Gross margin: 74.3%, -2.5pp YoY
- Business operating income: €2.08B, -7.7% YoY at CER
- Free cash flow: €2.34B, -25.5% YoY
- R&D expenses: €2.26B, +24.4% YoY
📌Business Highlights
- Received 14 regulatory approvals of medicines and vaccines in 2024
- Beyfortus achieved blockbuster status with €1.7B sales in first full year
- Plans to sell controlling stake in Opella consumer health business
🔮Future Outlook
- 2025 sales growth expected at mid-to-high single-digit percentage at CER
- Expects strong rebound in business EPS with low double-digit growth at CER
- Plans €5B share buyback program in 2025
- Dupixent sales expected to reach around €22B by 2030
Titres populaires
Meilleurs créateurs cette semaine